Sanofi (SNYNF) Return on Capital Employed (2018 - 2025)

Sanofi (SNYNF) posted Return on Capital Employed of 72.31% for Q4 2025, up 17.27% sequentially from 61.66% in Q2 2025.

Sanofi (SNYNF) Return on Capital Employed (2018 - 2025) Analysis & Trends

Sanofi (SNYNF) has 2 years of Return on Capital Employed data on file, last reported at 72.31% in Q4 2025.

Quarterly Return on Capital Employed changed N/A year-over-year to 72.31% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 72.31% (changed N/A YoY) and the FY2025 annual result came in at 6.61%, down 56.0% from the prior year.
Return on Capital Employed improved to 72.31% in Q4 2025 per SNYNF's latest filing, from 61.66% in the prior quarter.
The five-year high for Return on Capital Employed was 72.31% in Q4 2025, with the low at 61.66% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn	42.94%
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn	28.18%
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn	16.47%
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn	9.76%
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn	-5.22%
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn	15.87%
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn	21.53%
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn	-10.20%
9	Novartis Ag	113.45 Bn	113.67 Bn	-	-
10	Sanofi	-	-	9.49 Bn	-

Download Data